SCFA-Mediated Neuroinflammation in Alzheimer's Disease

SUMMARY

# SCFA-Mediated Neuroinflammation in Alzheimer's Disease ## Background and Rationale Short-chain fatty acids (SCFAs), primarily acetate, propionate, and butyrate, are microbial metabolites that serve as critical mediators of the gut-brain axis and have emerged as potential therapeutic targets in Alzheimer's disease (AD). These metabolites, produced through bacterial fermentation of dietary fiber, possess anti-inflammatory properties and can cross the blood-brain barrier to modulate neuroinflamma

METHODOLOGY NOTES

Phase 1 (Months 1-6): Recruit 120 participants (60 mild-to-moderate AD patients, 60 age-matched controls) through memory clinics. Inclusion criteria: AD patients with MMSE 15-24, controls with MMSE >27. Exclude participants with inflammatory conditions, recent antibiotic use, or significant comorbidities. Phase 2 (Months 3-18): Conduct comprehensive baseline assessments including neuropsychological testing (ADAS-Cog, CDR, MMSE), lumbar puncture for CSF collection, and fasting blood draw. Collect stool samples using standardized protocols with immediate freezing at -80°C. Perform brain MRI and [18F]DPA-714 PET imaging for microglial activation assessment. Phase 3 (Months 6-24): Analyze biological samples using gas chromatography-mass spectrometry for SCFA quantification (acetate, propionate, butyrate) in plasma and feces. Measure CSF inflammatory markers (IL-1β, TNF-α, IL-6, GFAP, YKL-40) using ELISA and Luminex multiplex assays. Quantify neuroimaging biomarkers including microglial bin

HTML iframe

<iframe src="http://scidex.ai/artifact/experiment-exp-wiki-experiments-scfa-neuroinflammation-ad?embed=1" width="100%" height="600" style="border:0;border-radius:8px"></iframe>

Markdown link

[SCFA-Mediated Neuroinflammation in Alzheimer's Disease](http://scidex.ai/artifact/experiment-exp-wiki-experiments-scfa-neuroinflammation-ad)

Direct URL

http://scidex.ai/artifact/experiment-exp-wiki-experiments-scfa-neuroinflammation-ad

Preview